Chuang, Victor - Curtin University

研究领域

Pharmaceutical Science Functionalisation of plasma proteins for therapeutic and drug delivery applications Recombinant therapeutic proteins including genetic fusion proteins Protein-protein and protein-ligand interactions Biopharmaceuticals and parenteral formulation and stability studies Pharmaceutical Practice Barriers to medication adherence - language, culture, disability

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Nagao, S., K. Taguchi, Y. Miyazaki, T. Wakayama, V. Chuang, K. Yamasaki, H. Watanabe, H. Sakai, M. Otagiri, and T. Maruyama. 2016.“Evaluation of a new type of nano-sized carbon monoxide donor on treating mice with experimentally induced colitis.”Journal of Controlled Release 234. In press. Taguchi, K., V. Chuang, K. Yamasaki, and M. Otagiri. 2015. “Pharmacokinetically modified human serum albumin based therapeutic design and development.” In Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses, 69-89. : . Kadowaki, D., S. Sakaguchi, Y. Miyamoto, K. Taguchi, N. Muraya, Y. Narita, K. Sato, V. Chuang, T. Maruyama, M. Otagiri et al. 2015.“Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment.”Biological and Pharmaceutical Bulletin 38 (3): 487-492. Taguchi, K., V. Chuang, K. Yamasaki, K. Kawai, T. Maruyama, T. Komatsu, and M. Otagiri. 2015.“The potential of a cross-linked human serum albumin dimer in diabetic rats as an augmenting agent for antidiabetic drugs.”Drug Metabolism Reviews 47: 237-237. Kinoshita, R., Y. Ishima, M. Ikeda, U. Kragh-Hansen, J. Fang, H. Nakamura, V. Chuang, R. Tanaka, H. Maeda, A. Kodama et al. 2015.“S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.”Journal of Controlled Release 217: 1-9. Maeda, H., K. Hirata, H. Watanabe, Y. Ishima, V. Chuang, H. Taguchi, A. Inatsu, M. Kinoshita, M. Tanaka, Y. Sasaki et al. 2015.“Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nano-antioxidant for the treatment of two acute hepatitis models.”Journal of Pharmacology and Experimental Therapeutics 352: 244-257. Taguchi, K., V. Chuang, K. Yamasaki, Y. Urata, R. Tanaka, M. Anraku, H. Seo, K. Kawai, T. Maruyama, T. Komatsu et al. 2015.“Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs.”Journal of Pharmacy and Pharmacology 67 (2): 255-263. Enoki, Y., Y. Ishima, R. Tanaka, K. Sato, K. Kimachi, T. Shirai, H. Watanabe, V. Chuang, Y. Fujiwara, M. Takeya et al. 2015.“Pleiotropic effects of levofloxacin, fluoroquinolone antibiotics, against influenza virus-induced lung injury.”PLoS One 10 (6): NA-NA. Nishida, K., H. Watanabe, S. Ogaki, A. Kodama, R. Tanaka, T. Imafuku, Y. Ishima, V. Chuang, M. Toyoda, M. Kondoh et al. 2015.“Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-Associated acute kidney injury.”Scientific Reports 5: 1-15. Kodama, A., H. Watanabe, R. Tanaka, M. Kondo, V. Chuang, Q. Wu, M. Endo, Y. Ishima, M. Fukagawa, M. Otagiri et al. 2014.“Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity.”Biochimica et Biophysica Acta - General Subjects 1840 (3): 1152-1162. Tanaka, R., Y. Ishima, Y. Enoki, K. Kimachi, T. Shirai, H. Watanabe, V. Chuang, T. Maruyama, and M. Otagiri. 2014.“Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice.”Frontiers in Immunology 5 (NOV). Tanaka, R., Y. Ishima, H. Maeda, A. Kodama, S. Nagao, H. Watanabe, V. Chuang, M. Otagiri, and T. Maruyama. 2014.“Albumin fusion prolongs the antioxidant and anti-inflammatory activities of thioredoxin in mice with acetaminophen-induced hepatitis.”Molecular Pharmaceutics 11 (4): 1228-1238. Ahmad, N., M. Mohd Amin, S. Mohd Mahali, I. Ismail, and V. Chuang. 2014.“Biocompatible and Mucoadhesive Bacterial Cellulose-g-Poly(acrylic acid) Hydrogels for Oral Protein Delivery.”Molecular Pharmaceutics 11: 4130-4142. Sato, H., V. Chuang, K. Yamasaki, N. Yamaotsu, H. Watanabe, K. Nagumo, M. Anraku, D. Kadowaki, Y. Ishima, S. Hirono et al. 2014.“Differential Effects of Methoxy Group on the Interaction of Curcuminoids with Two Major Ligand Binding Sites of Human Serum Albumin.”PLoS ONE 9 (2). Wahab Amjad, M., M. Mohd Amin, S. M. Mahali, H. Katas, I. Ismail, M. Naeem ul Hassan, and V. Chuang. 2014.“Nanoscale Diblock Copolymer Micelles: Characterizations and Estimation of the Effective Diffusion Coefficients of Biomolecules Release through Cylindrical Diffusion Model.”PLoS ONE 9 (8): 1-14. Nagumo, K., M. Tanaka, V. Chuang, H. Setoyama, H. Watanabe, N. Yamada, K. Kubota, M. Tanaka, K. Matsushita, A. Yoshida et al. 2014.“Cys34-Cysteinylated Human Serum Albumin Is a Sensitive Plasma Marker in Oxidative Stress-Related Chronic Diseases.”PLoS One 9 (1). Minomo, A., Y. Ishima, V. Chuang, Y. Suwa, U. Kragh-Hansen, T. Narisoko, H. Morioka, T. Maruyama, and M. Otagiri. 2013.“Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment.”Biochimica et Biophysica Acta - General Subjects 1830 (4): 2917-2923. Yamasaki, K., V. Chuang, T. Maruyama, and M. Otagiri. 2013.“Albumin-drug interaction and its clinical implication.”Biochimica et Biophysica Acta - General Subjects 1830: 5435-5443. Anraku, M., V. Chuang, T. Maruyama, and M. Otagiri. 2013.“Redox properties of serum albumin.”Biochimica et Biophysica Acta - General Subjects 1830: 5465-5472. Zhou, Y., R. Alany, V. Chuang, and J. Wen. 2013.“Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design.”Drug Development and Industrial Pharmacy 39 (2): 321-330.